Understanding SARS-CoV-2-Mediated Inflammatory Responses: From
Descrição
Currently there is no effective antiviral therapy for SARS-CoV-2 infection, which frequently leads to fatal inflammatory responses and acute lung injury. Here, we discuss the various mechanisms of SARS-CoV-mediated inflammation. We also assume that SARS-CoV-2 likely shares similar inflammatory responses. Potential therapeutic tools to reduce SARS-CoV-2-induced inflammatory responses include various methods to block FcR activation. In the absence of a proven clinical FcR blocker, the use of intravenous immunoglobulin to block FcR activation may be a viable option for the urgent treatment of pulmonary inflammation to prevent severe lung injury. Such treatment may also be combined with systemic anti-inflammatory drugs or corticosteroids. However, these strategies, as proposed here, remain to be clinically tested for effectiveness.
Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools
Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort study - The Lancet Microbe
COVID-19 Vaccines in Patients with Immune-Mediated Inflammatory Diseases – Consult QD
FASLG gene may drive cytokine-linked adverse COVID-19 outcomes with age
Platelets Can Associate With SARS-CoV-2 RNA and Are Hyperactivated in COVID-19
Frontiers Immune Response, Inflammation, and the Clinical Spectrum of COVID-19
Full article: JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy
Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19 - ScienceDirect
Physical activity and anti-inflammatory response in SARS-CoV2
Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools
Involvement of autophagy in lymphocyte-mediated inflammation during
Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome
COVID-19 therapeutics: Challenges and directions for the future
JCI - SARS–CoV-2–specific T cell responses and correlations with COVID-19 patient predisposition
de
por adulto (o preço varia de acordo com o tamanho do grupo)
